Molecular basis of intratumoral heterogeneity of urinary tract urothelial carcinoma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In the article the main mechanisms of molecular pathogenesis of urinary tract urothelial carcinoma are presented. Two different molecular pathways that determine the development of non-invasive and invasive urothelial carcinoma, the immunohistochemical spectrum of stem markers and aspects of the carcinogenesis of multifocal and recurrent tumors are considered.

Full Text

Restricted Access

About the authors

Y. I Osmanov

Scientific Clinical Center of Russian Railways; I.M. Sechenov First Moscow State Medical University

Email: osmanovyouseef@yandex.ru
Ph.D., head of the Department of Pathology; assistant professor of Department of Pathology named after A.I. Strukov

J. A Gaibov

Scientific Clinical Center of Russian Railways

Email: morf_jam.@mail.ru
pathologist at the Department of Pathology

E. A Kogan

I.M. Sechenov First Moscow State Medical University

Email: koganevg@gmail.com
MD, professor, Head of the Department of Pathology named after A.I. Strukov

L. M Rapoport

I.M. Sechenov First Moscow State Medical University

Email: leonidrapoport@yandex.ru
MD, professor, Deputy Director for Clinical Care of the Research Institute for Uronephrology and Human Reproductive Health

References

  1. Kirkali Z., Chan T., Manoharan M., Algaba F., Busch C., Cheng L. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis Urology. 2005;66(6) Suppl. 1:4-34. doi: 10.1016/j.urology.2005.07.062.
  2. Qu X., Huang X., Wu L. et al. Comparison of virtual cystoscopy and ultrasonography for bladder cancer detection: A meta-analysis. Eur J. Radiol. 2011;80(2):188-197. doi: 10.1016/j.ejrad.2010.04.003.
  3. Hall M.C., Chang S.S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 Update. J. Urol 2007;178:2314-2330. doi: 10.1016/j.juro.2007.09.003.
  4. Аль-Шукри А.С., Ткачук В.Н., Волков Н.М., Дубина М.В. Прогностические молекулярногенетические маркеры рака мочевого пузыря (обзор литературы). Онкоурология. 2009;(2):78-83
  5. Huguet J., Crego M., Sabat S. et al. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol. 2005;48(1):53-59.
  6. Заболотнева А.А., Гайфуллин Н.М., Буздин А.А., Алексеев Б.Я., Андреева Ю.Ю., Шегай П.В., Соков Д.Г., Русаков И.Г. Молекулярные маркеры рака мочевого пузыря: от частного к целому. Онкоурология. 2011;7(3): 16-19. Doi. org/10.17650/1726-9776-2011-7-3-16-19
  7. Brandt W.D., Matsui W. et al. Urothelialcarcinoma: Stemcellsontheedge. CancerMetastasisRev. 2009; 28(3-4): 291-304. doi: 10.1007/s10555-009-9187-6.
  8. Knowles M. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese. Carcinogenesis. 2006;27(3):361-73. doi: 10.1093/carcin/bgi310
  9. Pasin E., Josephson D., Anirban P. et al.Superficial bladder cancer: An update on etiology, molecular development, classification, and natural history. Rev Urol. 2008;10(1):31-43.
  10. Sanchez-Carbayo M., Cordon-Cardo C. Molecular alterations associated with bladder cancer progression. Semin Oncol. 2007;34(2):75-84. Doi: 10.1053/j. seminoncol.2006.12.013.
  11. Van Rhijn B., van der Kwast T., Vis A. et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;64:1911-1914.
  12. Bakkar A., Wallerand H., Radvanyi F. et al.FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63:8108-8112.
  13. Hernandez S., Lopez-Knowles E., Lloreta J.et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: Independent distribution and lack of association with prognosis. Clin Cancer Res. 2005;11:5444-5450.
  14. Jebar A., Hurst C., Tomlinson D. et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-25. doi: 10.1038/sj.onc.1208705.
  15. Inamura K. Bladder Cancer: New Insights into Its Molecular Pathology. Cancers (Basel). 2018;10(4). pii: E100. doi: 10.3390/cancers10040100.
  16. Hernandez S., Lopez-Knowles E., Lloreta J., Kogevinas M., Amoros A., Tardon A., Carrato A., Serra C., Malats N., Real F.X. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin Oncol. 2006;24(22):3664-71. doi: 10.1200/JC0.2005.05.1771.
  17. Wu X.R. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713-25. doi: 10.1038/nrc1697.
  18. Cheng J., Huang H., Pak J., Shapiro E., Sun T.T., Cordon-Cardo C., Waldman F.M., Wu X.R. Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res. 2003;63(1):179-185.
  19. Puzio-Kuter A.M., Castillo-Martin M., Kinkade C.W., Wang X., Shen T.H., Matos T., Shen M.M., Cordon-Cardo C., Abate-Shen C. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23(6):675-80. doi: 10.1101/gad.1772909.
  20. Netto G.J. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol.2012; 9:41-51. doi: 10.1038/nrurol.2011.193.
  21. Al-Sukhun S., Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer. 2003;97(8 Suppl.):2064-75. doi: 10.1002/cncr.11289.
  22. Zhang J., Niu C., Ye L., Huang H., He X., Tong W.G., Ross J., Haug J., Johnson T., Feng J.Q., et al. Identification of the haematopoietic stem cell niche and control ofthe niche size. Nature. 2003;425:836-841. doi: 10.1038/nature02041.
  23. Dick J.E., Magli M.C., Huszar D., Phillips R.A., Bernstein A. Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell. 1985;42(1):71-79.
  24. Gribben J.G., Hosing C., Maloney D.G. Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2011;17(1 Suppl):S63-S70. doi: 10.1016/j.bbmt.2010.10.011.
  25. Gerlinger M., Rowan A.J., Horswell S., Larkin J. et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N. Engl J. Med. 2012;366:883-892. doi: 10.1056/NEJMoa1113205.
  26. Gerlinger M., Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J. Cancer. 2010;103:1139-43. doi: 10.1038/sj.bjc.6605912.
  27. Navin N., Kendall J., Troge J. et al. Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90-94. Nature. 2011;472(7341):90-94. doi: 10.1038/nature09807.
  28. Bissell M.J., LaBarge M.A. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell. 2005;7(1): 17-23. doi: 10.1016/j.ccr.2004.12.013
  29. Campbell P.J., Pleasance E.D., Stephens P.J. et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA. 2008;105:13081-1386. Doi.org/10.1073/pnas.0801523105.
  30. Navin N., Krasnitz A., Rodgers L. et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20:68-80. doi: 10.1101/gr.099622.109.
  31. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta. 2010;1805:105-117. doi: 10.1016/j.bbcan.2009.11.002.
  32. He S., Nakada D., Morrison S.J. Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol. 2009;25:377-406. Doi: 0.1146/annurev.cellbio.042308.113248.
  33. Chan K.S., Espinosa I., Chao M., Wong D., Ailles L., Diehn M., Gill H., Presti J. Jr, Chang H.Y., van de Rijn M., Shortliffe L., Weissman IL. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA. 2009;106(33):14016-21. doi: 10.1073/pnas.0906549106.
  34. Cancer Genome Atlas Research Network.Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315-22. doi: 10.1038/nature12965.
  35. Choi W., Porten S., Kim S., Willis D., Plimack E.R., Hoffman-Censits J. et al. Identification of distinctbasal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:I52-65. doi: 10.1016/j.ccr.2014.01.009.
  36. Dong Fang and Hiroshi Kitamur. Cancer stem cells and epithelial-mesenchymal transition in urothelial carcinoma: Possible pathways and potential therapeutic approaches. International Journal of Urology. 2018;25:7-17. Doi: 10.1111/ iju.13404.
  37. Li Y., Linet K. et al. Bladder cancer stem cells: clonal origin and therapeutic perspectives. Oncotarget. 2017 ;8(39):66668-66679. Doi: 10.18632/ oncotarget.19112.
  38. Немцова М.В. Кушлинский Н.Е. Молекулярный патогенез рака мочевого пузыря. Альманах клинической медицины. 2015;10(41):79-88. Doi.org/10.18786/2072-0505-2015-41-79-88
  39. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer. 2002;2(3):210-19. doi: 10.1038/nrc755.
  40. Davidson D.D., Cheng L. “Field cancerization” in the urothelium of the bladder. Anal Quant Cytol Histol. 2006;28(6):337-338. PMID: 17220147.
  41. Paiss T., Wohr G., Hautmann R.E., Mattfeldt T., Muller M., Haeussler J., Vogel W. Some tumors of the bladder are polyclonal in origin. J. Urol. 2002;167(2 Pt 1):718-723.
  42. Slaughter D.P. et al. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6(5):963-968. PMID: 13094644.
  43. Williams J.M., Duckworth C.A., Burkitt M.D., Watson A.J.M. Epithelial Cell Shedding and Barrier Function. Vet Pathol. 2015;52(3):445-455. doi: 10.1177/0300985814559404.
  44. Owens M.B., Hill A.D.K., Hopkins A.M. Ductal barriers in mammary epithelium. Tissue Barriers. 20131;1(4):e25933. doi: 10.4161/tisb.25933.
  45. Podar K., Richardson P.G., Hideshima T., Chauhan D., Anderson K.C. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007;20(4):597-612. doi: 10.1016/j.beha.2007.08.002.
  46. Jones T.D., Wang M., Eble J.N., MacLennan G.T., Lopez-Beltran A., Zhang S., Cocco A., Cheng L. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005;11(18):651.2-9. doi: 10.1158/1078-0432.CCR-05-0891.
  47. Tabor M.P., Brakenhoff R.H., Ruijter-Schippers H.J., Van Der Wal J.E., Snow G.B., Leemans C.R., Braakhuis B.J. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J. Pathol. 2002;161(3):1051-60. doi: 10.1016/S0002-9440(10)64266-6.
  48. Wong D.J., Paulson T.G., Prevo L.J., Galipeau P.C., Longton G., Blount P.L., Reid B.J. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett’smetaplastic epithelium. Cancer Res. 2001;61(22):8284-8289.
  49. Hoglund M., On the origin of syn- and metachronous urothelial carcinomas. Eur Urol. 2007;5(1):11 85-93. doi: 10.1016/j.eururo.2006.11.025.
  50. Nordentoft I., Lamy P., Birkenkamp-Demtroder K., Shumansky K., Vang S., Hornshoj H. el al. Mutational context and diverse clonal development in early and late bladder cancer. Cell Rep. 2014;7: 1:649-63. Doi: 10.1016/j. celrep.2014.04.038. 51. van Tilborg A.A., de Vries A., de Bont M., Groenfeld L.E., van der Kwasl T.H., Zwarthoff E.C. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet. 2002;9:2973-2980.
  51. Dakubo G.D., Jakupciak J.P., Birch-Machin M.A., Parr R.L. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007;7:2. Doi: 10.1186/ 1475-2867-7-2
  52. Takahashi T., Kakehi Y., Mitsumori K., Akao T., Terachi T., Kato T., Ogawa O., Habuchi T. Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J Urol. 2001;165(2):672-677. doi: 10.1097/00005392-200102000-00092

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies